Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients.
| Website | http://www.avectas.com |
| Employees | 31 (27 on RocketReach) |
| Founded | 2011 |
| Technologies |
JavaScript
,
HTML
,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology Research, Cell Engineering, Transfection, Cell Therapy, CAR-T, Gene Editing, Gene Therapy, CRISPR |
| Keywords | Cell Therapy, Gene Editing, Drug Delivery, Regenerative Medicine, Cell Therapies, Gene Therapy, Drug Development, Cell Manufacturing, Cell Engineering, Genome Editing, Pharmaceutical, Platform Technology, Advanced Therapy Medicinal Products, Cellular Therapies, Genetic Engineering, Biotechnology, Delivery Platform, Biopharma, Healthcare Technology, Medical Technology |
| Competitors | Novartis, Amgen, Gilead Sciences, Intellia Therapeutics, Inc., CRISPR Therapeutics, Editas Medicine, Zymeworks Inc., Cellectis, Athersys, Glycostem Therapeutics +56 more (view full list) |
Looking for a particular Avectas employee's phone or email?
Avectas Questions
Michael Maguire is the CEO of Avectas.
27 people are employed at Avectas.
Top Avectas Employees
-
Michael Maguire
Chief Executive Officer at Avectas
Cambridge, MA, US23 -
22
-
Kieran Reilly
Director, Finance at Avectas
Dublin, IE11
Related Companies
